Release Summary

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients Locally Advanced or Metastatic Urothelial Carcinoma

Bristol-Myers Squibb Company